Amantadine's role in the treatment of levodopa-induced dyskinesia.
作者信息
Rodnitzky Robert L, Narayanan Nandakumar S
机构信息
From the Department of Neurology (R.L.R., N.S.N.), and Aging, Mind, and Brain Initiative (N.S.N.), University of Iowa College of Medicine, Iowa City.
出版信息
Neurology. 2014 Jan 28;82(4):288-9. doi: 10.1212/WNL.0000000000000068. Epub 2013 Dec 26.
Abstract
摘要
相似文献
1
Amantadine's role in the treatment of levodopa-induced dyskinesia.金刚烷胺在治疗左旋多巴诱发的异动症中的作用。
Neurology. 2014 Jan 28;82(4):288-9. doi: 10.1212/WNL.0000000000000068. Epub 2013 Dec 26.
2
Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.缓释金刚烷胺（Gocovri）用于治疗帕金森病的运动障碍。
Med Lett Drugs Ther. 2017 Dec 4;59(1535):198-200.
3
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.金刚烷胺用于治疗GCH1基因突变复合杂合子中左旋多巴诱导的舞蹈症性运动障碍。
Mov Disord. 2004 Oct;19(10):1256-8. doi: 10.1002/mds.20194.
4
The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.金刚烷胺对帕金森病左旋多巴诱发异动症的影响：一项双盲、安慰剂对照研究。
Clin Neuropharmacol. 2000 Mar-Apr;23(2):82-5. doi: 10.1097/00002826-200003000-00004.
5
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.金刚烷胺治疗左旋多巴诱发的异动症：一项为期1年的随访研究。
Arch Neurol. 1999 Nov;56(11):1383-6. doi: 10.1001/archneur.56.11.1383.
6
The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.缓释金刚烷胺在帕金森病患者运动障碍治疗中的作用。
Neurodegener Dis Manag. 2018 Apr;8(2):73-80. doi: 10.2217/nmt-2018-0001. Epub 2018 Mar 22.
7
Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia.左旋多巴诱导运动障碍的药物治疗新进展
Drugs. 2019 Sep;79(13):1367-1374. doi: 10.1007/s40265-019-01170-5.
8
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).ADDS-5102（金刚烷胺）控释胶囊治疗帕金森病左旋多巴诱导运动障碍的随机、安慰剂对照试验（EASE LID 3）。
Mov Disord. 2017 Dec;32(12):1701-1709. doi: 10.1002/mds.27131. Epub 2017 Aug 21.
9
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).金刚烷胺缓释剂治疗帕金森病左旋多巴诱导的异动症（EASED研究）。
Mov Disord. 2015 May;30(6):788-95. doi: 10.1002/mds.26159. Epub 2015 Feb 4.
10
[Parkinson's Disease with Intolerable Painful Dyskinesia: Standard Treatment and Subsequent Tips].
Brain Nerve. 2022 May;74(5):468-473. doi: 10.11477/mf.1416202066.
引用本文的文献
1
Quinpirole inhibits levodopa-induced dyskinesias at structural and behavioral levels: Efficacy negated by co-administration of isradipine.喹吡罗抑制左旋多巴诱导的运动障碍在结构和行为水平：协同给予异搏定疗效被否定。
Exp Neurol. 2023 Nov;369:114522. doi: 10.1016/j.expneurol.2023.114522. Epub 2023 Aug 26.
2
The Lisbon Supramolecular Green Story: Mechanochemistry towards New Forms of Pharmaceuticals.《里斯本超分子绿色故事：机械化学在新型药物中的应用》
Molecules. 2020 Jun 11;25(11):2705. doi: 10.3390/molecules25112705.
3
Update on the Management of Parkinson's Disease for General Neurologists.普通神经科医生帕金森病管理的最新进展
Parkinsons Dis. 2020 Mar 26;2020:9131474. doi: 10.1155/2020/9131474. eCollection 2020.
4
Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases.神经凝血病学：中枢神经系统疾病中的凝血因子。
Int J Mol Sci. 2017 Oct 12;18(10):2128. doi: 10.3390/ijms18102128.
5
New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease.针对神经精神疾病的靶向 D1 型多巴胺受体的新治疗策略。
Front Biol (Beijing). 2015 Jun;10(3):230-238. doi: 10.1007/s11515-015-1360-4. Epub 2015 May 13.
6
Approved Antiviral Drugs over the Past 50 Years.过去50年中获批的抗病毒药物。
Clin Microbiol Rev. 2016 Jul;29(3):695-747. doi: 10.1128/CMR.00102-15.
7
Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.纹状体胆碱能中间神经元的光遗传学激活可调节左旋多巴诱发的运动障碍。
Neurobiol Dis. 2016 Jul;91:47-58. doi: 10.1016/j.nbd.2016.02.019. Epub 2016 Feb 24.
8
Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications.帕金森病及其管理：第4部分：运动并发症的治疗。
P T. 2015 Nov;40(11):747-73.
9
α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.α7烟碱受体激动剂可减轻伴有严重黑质纹状体损伤的左旋多巴诱发的异动症。
Mov Disord. 2015 Dec;30(14):1901-1911. doi: 10.1002/mds.26453. Epub 2015 Nov 17.
10
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.单侧6-羟基多巴胺损伤大鼠模型中A2a/NR2B组合的行为学评估：一种检测非多巴胺能药物治疗潜力的新方法。
PLoS One. 2015 Aug 31;10(8):e0135949. doi: 10.1371/journal.pone.0135949. eCollection 2015.
本文引用的文献
1
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.帕金森病运动障碍患者中停用金刚烷胺：AMANDYSK 试验。
Neurology. 2014 Jan 28;82(4):300-7. doi: 10.1212/WNL.0000000000000050. Epub 2013 Dec 26.
2
Which dyskinesia scale best detects treatment response?哪种运动障碍量表最能检测到治疗反应？
Mov Disord. 2013 Mar;28(3):341-6. doi: 10.1002/mds.25321. Epub 2013 Feb 6.
3
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.运动障碍学会循证医学综述更新：帕金森病运动症状的治疗方法。
Mov Disord. 2011 Oct;26 Suppl 3:S2-41. doi: 10.1002/mds.23829.
4
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.左旋多巴诱导运动障碍的发病机制及表达及其药物干预的机制。
J Neural Transm (Vienna). 2011 Dec;118(12):1661-90. doi: 10.1007/s00702-011-0698-2. Epub 2011 Sep 1.
5
Molecular mechanisms of L-DOPA-induced dyskinesia.左旋多巴诱发异动症的分子机制。
Nat Rev Neurosci. 2008 Sep;9(9):665-77. doi: 10.1038/nrn2471.
6
Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.悉尼帕金森病多中心研究：15年后非左旋多巴反应性问题占主导地位。
Mov Disord. 2005 Feb;20(2):190-9. doi: 10.1002/mds.20324.
7
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.左旋多巴诱发异动症中多巴胺D1受体信号增强。
Ann Neurol. 2005 Jan;57(1):17-26. doi: 10.1002/ana.20296.
8
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.金刚烷胺对重度帕金森病运动障碍的疗效持续时间。
J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):141-3.
Zotero 插件